The U.S. decision in January to freeze all funding for U.S. foreign assistance, including for the U.S. President's Emergency ...

A team of researchers from the University of Florida has developed an innovative handheld device for human immunodeficiency ...

The FDA has accepted a priority review of a new biannual HIV prevention injection, with a decision expected by June 19, 2025.

PRESS RELEASE Urgent and accelerated delivery of HIV services is critical to end AIDS by 2030 Gujarat Chief Minister Shri ...

Analysts at RBC Capital Markets have predicted twice-yearly lenacapavir could become a $2 billion product, and become a key ...

Lenacapavir is a twice-yearly injectable medication designed to be used as pre-exposure prophylaxis (PrEP). The FDA is giving ...

Viruses, like those that cause COVID-19 or HIV, are formidable opponents once they invade our bodies. Antiviral treatments strive to block a virus or halt its replication. However, viruses are dynamic ...

Deutsche Bank upgraded Gilead Sciences (NASDAQ:GILD) on Tuesday, citing the antiviral developer’s HIV treatment franchise, and downgraded Merck (NYSE:MRK), citing the cancer drugmaker’s upcoming loss ...

By paralyzing frontline response efforts led by community groups, the US decision to freeze funding is weakening health systems across the Global South. The freeze not only jeopardizes precious gains ...

The FDA has accepted Gilead Sciences’ new drug application for lenacapavir as a long-lasting injectable to prevent HIV ...

An HIV drug was named “2024 Breakthrough of the Year” by Science Magazine. Biochemistry research from the University of Utah ...